Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Clinical trial NCT04411641 · COMPLETED

Trial details

NCT number: NCT04411641
Sponsor: Sanofi
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Non-relapsing Secondary Progressive Multiple Sclerosis

Start date: 2020-09-24
Primary completion: 2024-08-29
Enrollment: 1131

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.